Testing effectiveness (Phase 2)Study completedNCT00305734
What this trial is testing
Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer
Who this might be right for
Recurrent Nasopharyngeal CancerStage IV Nasopharyngeal Cancer
National Cancer Institute (NCI) 50